Qiagen to Seek FDA OK Next Year for Two Genaco Panels; Consumables Drive Strong Q2 Growth | GenomeWeb
This article has been updated from a previous version that incorrectly stated that 7 percent of Qiagen's revenue came from Genaco. The article should have stated that 7 percent of Qiagen's third quarter revenue came from acquisitions.
 
Qiagen officials said this week that the company would seek US Food and Drug Administration clearance next year to market two PCR-based multiplex panels developed by the recently acquired Genaco Biomedical.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.